Track topics on Twitter Track topics that are important to you
NEW YORK, June 6, 2017 /PRNewswire/ --
According to a research report published by Arcview Market Research, the growth of the legal cannabis market is projected to reaccelerate beginning in 2018. Adult use sales would ramp up in Canada, California, and Massachusetts along with medical sales in Florida. The current growth in the sector has been $6.7-billion market in 2016 at a robust 27% CAGR to $22.6 billion in 2021. For the cannabis industry, the biggest political victory came in the U.S. elections in California. California voted overwhelmingly in 2016 to make adult use legal in a state that represents the world's sixth-largest economy. ChineseInvestors.com, Inc. (OTC: CIIX), AXIM Biotechnologies, Inc. (OTC: AXIM), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Vitality Biopharma, Inc. (OTC: VBIO), Cannabis Sativa. Inc. (OTC: CBDS)
A major component of the legal cannabis industry is the CBD market. Matt Karnes of Greenwave Advisors is even more optimistic about the growth of the CBD market saying, "In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now, there are 15 states that allow CBD only - this is in addition to the 28 states plus DC that have legalized medical marijuana," Forbes reported. Outco, the largest licensed cultivator in Southern California learned that 38% of users and non-users said they wanted to learn more about CBD oil. Forbes indicated that Outco also believes the market is poised for growth.
ChineseInvestors.com, Inc. (OTCQB: CIIX) earlier today announced, "that it has formally engaged Launch Haus, LLC ('Launch Haus'), venture building firm and digital holding company, based in Scottsdale, AZ, specializing in direct response marketing including digital, ecommerce, and direct sales channels. Launch Haus will play an integral part in directing the Company's organization and launch of its direct-to-consumer ecommerce and network marketing business divisions."
Launch Haus has a strong presence in the direct-selling industry and its principals have a proven track record having built sales organizations with an excess of $1.5 billion in commissionable volume over the last 10 years. "We are very excited to work with ChineseInvestors.com, Inc. on its new campaign and believe that the Company can successfully implement its unique, customer-centric business model, which aims to provide health conscious consumers with amazing hemp-based products and an equally amazing international business opportunity," said Chris J. Snook, Managing Partner at Launch Haus, LLC and author of Digital Sense (Wiley, 2017).
Following the Company's impressive third quarter financial reports, CIIX believes that it is on track to announce an official launch date of its direct selling platform in the coming fiscal year. "Launch Haus is the perfect firm to oversee CIIX's direct response marketing campaign which will include significant direct to consumer ecommerce channels such as Amazon and development of the Company's international network marketing platform as we begin to drive revenues in the coming fiscal year. We are prepared for rapid domestic and international expansion," said Warren Wang CEO of CIIX.
Highlights of the engagement: In addition to general go-to-market planning and customer experience consulting, Launch Haus has been engaged to: - Develop a customized cutting-edge direct response marketing campaign that will focus on personalized, customer-centric marketing and sales force automation. - Develop a compensation plan that incentivizes both rapid growth through recruitment of new, entry-level consumers and top-tier distributors. - Introduce CIIX to its stable of industry-leading suppliers for global payment systems and logistics and its network of distributor recruitment and legal governance and compliance professionals.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Recently, the company announced that its product development partner Quay Pharmaceuticals Ltd. ('Quay Pharma') has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM's MedChew Rx® pharmaceutical chewing gum's family of products. MedChew Rx® - formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC) - is being developed as a pharmaceutical drug to treat pain and spasticity associated with multiple sclerosis (MS).
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is developing therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol (CBD), a non-psychoactive cannabinoid, and tetrahydrocannabinol (THC). ZYN002, the Company's CBD gel, is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel. In March 2017, the Company completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial of ZYN002 CBD gel in refractory epilepsy patients with focal seizures, the most common form of epilepsy in adults.
Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. On April, 2017, the company announced the filing of an international patent application in March 2017 that describes compounds discovered to be effective in a drug screening model of neural repair. "Part of our mission is to develop treatments that provide far more than symptomatic relief," said Robert Brooke, Chief Executive Officer of Vitality Biopharma. "We're excited to further explore the ability of CBD and similar compounds to deliver regenerative benefits for patients with MS and other demyelinating conditions."
On April 10, 2017, Cannabis Sativa. Inc. (OTCQB: CBDS) announced that it entered into an agreement to acquire the intellectual property for the White Rabbit brand of cannabis sprays and cannabis mints. The acquisition will include the exclusive and proprietary product formulations, product mixes, manufacturing methods and branding. The White Rabbit product line currently consists of fast-acting low dose cannabis oral sprays and popular low dose cannabis mints. Both the spray and the mints are formulated as CBD only, THC only and CBD/THC blends.
Please sign up now at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: email@example.com
SOURCE FinancialBuzz.comNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...